Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12627108 | 0.92 | HCRTR1 (0.48) | HCRTR1HCRTR2L3MBTL1ALDH1A1NAMPT | |
| SCHEMBL15426422 | 0.89 | HCRTR1 (0.51) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL12655883 | 0.88 | HCRTR1 (0.50) | HCRTR1HCRTR2L3MBTL1ALDH1A1NAMPT | |
| SCHEMBL12627185 | 0.88 | HCRTR1 (0.50) | HCRTR1HCRTR2L3MBTL1ALDH1A1MMP13 | |
| SCHEMBL12656193 | 0.87 | L3MBTL1 (0.57) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL15426424 | 0.86 | HCRTR1 (0.48) | HCRTR1HCRTR2L3MBTL1ALDH1A1 | |
| SCHEMBL15693680 | 0.84 | L3MBTL1 (0.43) | HCRTR1HCRTR2L3MBTL1ALDH1A1GPR119 | |
| SCHEMBL12621885 | 0.82 | HCRTR1 (0.53) | HCRTR1HCRTR2L3MBTL1ALDH1A1 | |
| SCHEMBL12626093 | 0.79 | L3MBTL1 (0.54) | HCRTR1HCRTR2L3MBTL1MMP2MMP13 | |
| SCHEMBL12622084 | 0.79 | HCRTR2 (0.73) | HCRTR1HCRTR2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | BURNS BARBIER LINDSAY (US) | 2016-09-01 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251374-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR1 3880/4885HCRTR2 3876/4885L3MBTL1 3291/4885 |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, FPR1 | HCRTR1 4172/4885HCRTR2 4089/4885L3MBTL1 4055/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR1 3880/4885HCRTR2 3876/4885L3MBTL1 3291/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885L3MBTL1 1789/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | HCRTR1 3430/4885HCRTR2 3778/4885L3MBTL1 1041/4885 |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR1 3880/4885HCRTR2 3876/4885L3MBTL1 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.